Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Pfizer : Capitol Alert

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 10:06am CEST

Oct. 06--California state Sen. Ed Hernandez, Democrat campaigning for lieutenant governor next year as a crusader against major drug companies, hasn't always been their adversary.

Hernandez is the author of heavily lobbied drug-price transparency legislation, Senate Bill 17, that's currently sitting on Gov. Jerry Brown's desk. The Azusa optometrist also recently released a digital campaign video for his 2018 race that says he "took on big pharma" to prevent price gouging and make life-saving medications more affordable.

The video, featuring a testimonial from activist and singer Kendall Renee, focuses on the soaring costs of EpiPen. The drug is made by Mylan, Inc. Manufacturers include Meridian Medical Technologies, which is owned by the drug giant Pfizer. A Hernandez campaign news release announcing the EpiPen video describes him as "unshaken by big moneyed special interests."

A Sacramento Bee review of Hernandez's political contributions and voting patterns, however, suggest a mixed record of taking on the drug companies. Between 2011 and this June, Hernandez, who chairs the Senate Health Committee, accepted at least $207,411 from drug-makers and their interests, including $11,200 from Pfizer. Mylan Laboratories PAC wrote him a $1,500 check in 2008, state records show.

Hernandez has been the Legislature's top recipient of drug-maker money since 2011, far ahead of the second-highest recipient, Republican Assemblyman Brian Maienschein, who received $152,939. Maienschein's San Diego-based district includes many leading life science industry firms.

Hernandez transferred more than $70,000 from pharmaceutical manufacturers and lobbying groups into the 2018 election to help position himself as the frontrunner for lieutenant governor. The crowded field includes Democrats Eleni Kounalakis, former U.S. ambassador to Hungary, Jeff Bleich, former U.S. ambassador to Australia and Asif Mahmood, a Los Angeles physician.

While accepting the money, Hernandez's voting interests sometimes aligned with the drug industry's goals. In 2011-12, for example, Pfizer lobbied on three Hernandez bills that would become law.

Senate Bill 1301 authorized a pharmacist to dispense a 90-day supply of a drug -- other than a controlled substance or psychotropic medication -- pursuant to a prescription for a lesser amount if the patient completed an initial 30-day supply of the medication, and other conditions were met.

Senate Bill 1524 deleted a requirement that certified nurse-midwives and nurse practitioners complete six months of supervised training to be allowed to furnish or order drugs or devices. Instead, it allowed physicians and surgeons to decide the extent of supervision needed to furnish or order drugs and devices.

Senate Bill 866, supported by the Pharmaceutical Research and Manufacturers of America, required that the state Department of Managed Health Care and Department of Insurance develop a uniform "prior-authorization" form that health plans and insurers would accept when prescribing providers seek authorization for prescription drug benefits.

A spokeswoman for the drug manufacturing association said the organization does not comment on political contributions.

Hernandez's campaign spokesman, Dave Jacobson, acknowledged the past donations and votes, but contended that "Senator Hernandez understands that we have a rigged campaign finance system and that it's an unfortunate reality that candidates have to raise such an obscene amount of money to fund campaigns."

Jacobson said special interests have spent millions in advertising and lobbying to defeat Hernandez's legislative efforts because of his record of "going to war against Big Pharma, Big Tobacco and Big Insurance" -- noting his support of the drug transparency policy, raising California's smoking age to 21 and advancing single-payer health care legislation.

Hernandez's drug transparency measure drew big opposition from PhRMA, Biocom and Eli Lilly after drug companies successfully beat back similar legislation and a statewide ballot measure last year. Hernandez's bill requires health plans and insurers to break down and report premium and drug cost information to the state.

Supporters say that would provide the state with data on the percentage of premiums and increases in premiums that can be attributed to prescription drug costs.

Christopher Cadelago: 916-326-5538, @ccadelago


(c)2017 The Sacramento Bee (Sacramento, Calif.)

Visit The Sacramento Bee (Sacramento, Calif.) at www.sacbee.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
06/22PFIZER : Alation Recognized as a Leader in Machine Learning Data Catalogs report..
06/22PFIZER : Invites Public to View and Listen to Webcast of July 31 Conference Call..
06/21PFIZER : New Findings from Pfizer Describe Advances in Breast Cancer (Small mole..
06/21PFIZER : An Application for the Trademark "ON EVERYONE'S LIPS" Has Been Filed by..
06/21PFIZER : Trademark Application for "DAURIANA" Filed by Pfizer
06/21PFIZER : Trademark Application for "THE POWER OF ONE" Filed by Pfizer
06/21PFIZER : Announces Extension of Zithromax® Antibiotic Donation Program through 2..
06/21PFIZER : Researchers from Pfizer Describe Findings in Candida (Echinocandins for..
06/21PFIZER : Recent Findings from Pfizer Has Provided New Information about Polyethy..
06/21Mediaocean And IBM Partner To Integrate Blockchain Across The Media Ecosystem
More news
News from SeekingAlpha
06/22VOYAGER : A Leader In Neurological Gene Therapy Receives RMAT Designation 
06/21Neon Therapeutics Firms Its Plan For $100 Million IPO 
06/21Forty Seven Readies $100 Million U.S. IPO 
06/213 THINGS IN BIOTECH, JUNE 20 : Bristol Burns Up The Myeloma World 
06/20Gene Therapy For Duchenne 
Financials ($)
Sales 2018 54 378 M
EBIT 2018 20 777 M
Net income 2018 12 874 M
Debt 2018 21 838 M
Yield 2018 3,74%
P/E ratio 2018 16,79
P/E ratio 2019 15,19
EV / Sales 2018 4,33x
EV / Sales 2019 4,13x
Capitalization 214 B
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 39,9 $
Spread / Average Target 9,2%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER0.00%213 568
JOHNSON & JOHNSON-12.27%327 330
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
AMGEN7.07%123 415